Form 4: Aardvark Therapeutics CEO Boosts Stake
Insider Transaction Report
Aardvark Therapeutics CEO and 10% owner Tien-Li Lee purchased 10,000 shares of common stock for approximately $96,800.
Summary
- Tien-Li Lee, who serves as Chief Executive Officer, Director, and a 10% owner of Aardvark Therapeutics, Inc. (AARD), acquired a total of 10,000 shares of the company's common stock.
- The transactions occurred on September 15, 2025.
- One purchase involved 6,500 shares at a weighted average price of $9.5106 per share, with prices ranging from $8.9045 to $9.89.
- A second purchase involved 3,500 shares at a weighted average price of $9.9442 per share, with prices ranging from $9.93 to $9.9798.
- Following these acquisitions, Tien-Li Lee directly holds 1,543,384 shares of common stock.
- Additionally, Tien-Li Lee indirectly beneficially owns 1,474,028 shares through a spouse.
Sentiment
Score: 7
Explanation: The purchase of shares by a CEO and 10% owner generally indicates confidence in the company's future prospects, which is a positive signal for investors.
Positives
- The Chief Executive Officer and a 10% owner, Tien-Li Lee, increased direct beneficial ownership by 10,000 shares, signaling strong insider confidence in the company's future.
- The total value of the shares purchased by the insider amounts to approximately $96,800, representing a notable personal investment.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Tien-Li Lee's indirect beneficial ownership of 1,474,028 shares is held by a spouse.
Stakeholder Impact
- Shareholders may interpret the insider purchase as a strong vote of confidence from management, potentially leading to increased investor interest and positive sentiment towards the company's stock.
Key Dates
| Date | Description |
|---|---|
| 09/15/2025 | Date of common stock purchase transactions by Tien-Li Lee. |
| 09/16/2025 | Date the Form 4 was signed and filed by the reporting person. |
Recommendation
buyThe significant purchase of common stock by Tien-Li Lee, who serves as both CEO and a 10% owner, signals strong insider confidence in Aardvark Therapeutics' future prospects. This direct investment by a key executive and major shareholder suggests a belief that the company's stock is currently undervalued or poised for growth, making it a favorable indicator for potential investors.
Keywords
Aardvark Therapeutics, AARD, Tien-Li Lee, Insider Buying, Common Stock, CEO, Director, 10% Owner, SEC Form 4, Stock Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.